BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34576138)

  • 1. Design and Synthesis of Water-Soluble and Potent MMP-13 Inhibitors with Activity in Human Osteosarcoma Cells.
    Zapico JM; Acosta L; Pastor M; Rangasamy L; Marquez-Cantudo L; Coderch C; Ortin I; Nicolau-Sanus M; Puchades-Carrasco L; Pineda-Lucena A; Majali-Martinez A; Ramos P; de Pascual-Teresa B; Ramos A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress towards water-soluble triazole-based selective MMP-2 inhibitors.
    Fabre B; Filipiak K; Zapico JM; Díaz N; Carbajo RJ; Schott AK; Martínez-Alcázar MP; Suárez D; Pineda-Lucena A; Ramos A; de Pascual-Teresa B
    Org Biomol Chem; 2013 Oct; 11(38):6623-41. PubMed ID: 23989288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of ferulic Acid amides as selective matrix metalloproteinase inhibitors.
    Shi ZH; Li NG; Shi QP; Tang H; Tang YP; Li W; Yin L; Yang JP; Duan JA
    Med Chem; 2013 Nov; 9(7):947-54. PubMed ID: 23061601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
    Yuan H; Lu W; Wang L; Shan L; Li H; Huang J; Sun Q; Zhang W
    Eur J Med Chem; 2013 Apr; 62():148-57. PubMed ID: 23353736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugar-Based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 Inhibitors.
    Nuti E; Cuffaro D; D'Andrea F; Rosalia L; Tepshi L; Fabbi M; Carbotti G; Ferrini S; Santamaria S; Camodeca C; Ciccone L; Orlandini E; Nencetti S; Stura EA; Dive V; Rossello A
    ChemMedChem; 2016 Aug; 11(15):1626-37. PubMed ID: 27356908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydantoin based inhibitors of MMP13--discovery of AZD6605.
    De Savi C; Waterson D; Pape A; Lamont S; Hadley E; Mills M; Page KM; Bowyer J; Maciewicz RA
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4705-12. PubMed ID: 23810497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold.
    Cheng XC; Wang RL; Dong ZK; Li J; Li YY; Li RR
    Bioorg Med Chem; 2012 Oct; 20(19):5738-44. PubMed ID: 22967811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.
    Agamennone M; Belov DS; Laghezza A; Ivanov VN; Novoselov AM; Andreev IA; Ratmanova NK; Altieri A; Tortorella P; Kurkin AV
    ChemMedChem; 2016 Sep; 11(17):1892-8. PubMed ID: 27418256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
    Ramezani M; Shamsara J
    Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
    Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
    J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
    Chen C; Yang X; Fang H; Hou X
    Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.
    Knapinska AM; Singh C; Drotleff G; Blanco D; Chai C; Schwab J; Herd A; Fields GB
    ChemMedChem; 2021 Apr; 16(7):1133-1142. PubMed ID: 33331147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.
    Spicer TP; Jiang J; Taylor AB; Choi JY; Hart PJ; Roush WR; Fields GB; Hodder PS; Minond D
    J Med Chem; 2014 Nov; 57(22):9598-611. PubMed ID: 25330343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.